HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price

Oculis (NASDAQ:OCS) had its target price upped by HC Wainwright from $33.00 to $36.00 in a report released on Tuesday morning, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock.

OCS has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Saturday, September 27th. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research note on Sunday, September 21st. Finally, Needham & Company LLC started coverage on Oculis in a report on Wednesday, August 27th. They set a “buy” rating and a $36.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Oculis presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.50.

Oculis Stock Up 2.7%

OCS stock opened at $19.06 on Tuesday. The business’s 50-day moving average price is $17.54 and its 200-day moving average price is $18.07. The stock has a market cap of $832.16 million, a P/E ratio of -7.14 and a beta of 0.29. The company has a quick ratio of 4.55, a current ratio of 4.55 and a debt-to-equity ratio of 0.01. Oculis has a twelve month low of $14.00 and a twelve month high of $23.08.

Oculis (NASDAQ:OCS) last released its earnings results on Thursday, August 21st. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.06). Oculis had a negative return on equity of 90.31% and a negative net margin of 13,958.12%.The firm had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.14 million. On average, equities research analysts forecast that Oculis will post -2.09 EPS for the current year.

Institutional Investors Weigh In On Oculis

Institutional investors have recently added to or reduced their stakes in the stock. Kestra Private Wealth Services LLC purchased a new stake in Oculis during the 1st quarter valued at approximately $234,000. Bosun Asset Management LLC purchased a new stake in Oculis during the 2nd quarter valued at approximately $378,000. Marshall Wace LLP purchased a new stake in Oculis during the 2nd quarter valued at approximately $393,000. Bank of America Corp DE grew its holdings in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after buying an additional 10,667 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after buying an additional 6,384 shares in the last quarter. 22.30% of the stock is owned by hedge funds and other institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.